期刊
NATURE MEDICINE
卷 8, 期 5, 页码 485-492出版社
NATURE AMERICA INC
DOI: 10.1038/nm0502-485
关键词
-
资金
- NICHD NIH HHS [HD32573] Funding Source: Medline
- NIDDK NIH HHS [R01 DK053428, DK53428, DK50203, DK17433] Funding Source: Medline
- NIGMS NIH HHS [GM42136] Funding Source: Medline
The most common mutation in cystic fibrosis, DeltaF508, results in a cystic fibrosis transmembrane conductance regulator (CFTR) protein that is retained in the endoplasmic reticulum (ER). Retention is dependent upon chaperone proteins, many of which require Ca++ for optimal activity. Interfering with chaperone activity by depleting ER Ca++ stores might allow functional DeltaF508-CFTR to reach the cell surface. We exposed several cystic fibrosis cell lines to the ER Ca++ pump inhibitor thapsigargin and evaluated surface expression of DeltaF508-CFTR. Treatment released ER-retained DeltaF508-CFTR to the plasma membrane, where it functioned effectively as a Cl- channel. Treatment with aerosolized calcium-pump inhibitors reversed the nasal epithelial potential defect observed in a mouse model of DeltaF508-CFTR expression. Thus, ER calcium-pump inhibitors represent a potential target for correcting the cystic fibrosis defect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据